antihemophilic factor viii (Recombinant) (Adynovate) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII. Certain preparations may also be used in those with von Willebrand's disease. It is given by slow injection into a vein.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

advate | adynovate | antihemophilic factor, human (monoclonal) | antihemophilic factor, human recombinant | antihemophilic factor recombinant | antihemophilic factor (recombinant) | antihemophilic factor,recombinant | antihemophilic factor, recombinant | antihemophilic factor (recombinant), pegylated | antihemophilic factor (recombinant), plasma/albumin-free method | antihemophilic factor (recombinant), rahf | bax 855 | bay 14-2222 | bay-14-2222 | bay14-2222 | bay 81-8973 | bay94-9027 | bebulin | factor viii (rdna) | factor viii recombin | factor viii (recombinant) | factor viii, recombinant | greengene f | human coagulation factor viii / human von willebrand factor | human factor viii recombinant | human factor viii (recombinant) | iblias | monoclate | monoclate-p | monoelate-p | nuwiq | octocog alfa | pegylated recombinant factor viii | rahf | recombinant antihemophilic factor | recombinant antihemophilic factor viii | recombinant coagulation factor | recombinate | recombinate | sct800

Organizations (49)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Hemophilia A (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Bleeding Time (Phase 4)

Bone Diseases (Phase 3)

Child (Phase 3)

Factor VIII (Phase 4)

Hemophilia A (Phase 4)

Hemophilia B (Phase 3)

Hemorrhage (Phase 4)

Immune Tolerance (Phase 4)

Traumatology (Phase 4)

von Willebrand Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 70
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue